Cargando…
The Emerging Role of Epigenetics in Therapeutic Targeting of Cardiomyopathies
Cardiomyopathies (CMPs) are a heterogeneous group of myocardial diseases accountable for the majority of cases of heart failure (HF) and/or sudden cardiac death (SCD) worldwide. With the recent advances in genomics, the original classification of CMPs on the basis of morphological and functional cri...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395924/ https://www.ncbi.nlm.nih.gov/pubmed/34445422 http://dx.doi.org/10.3390/ijms22168721 |
_version_ | 1783744281680281600 |
---|---|
author | Pagiatakis, Christina Di Mauro, Vittoria |
author_facet | Pagiatakis, Christina Di Mauro, Vittoria |
author_sort | Pagiatakis, Christina |
collection | PubMed |
description | Cardiomyopathies (CMPs) are a heterogeneous group of myocardial diseases accountable for the majority of cases of heart failure (HF) and/or sudden cardiac death (SCD) worldwide. With the recent advances in genomics, the original classification of CMPs on the basis of morphological and functional criteria (dilated (DCM), hypertrophic (HCM), restrictive (RCM), and arrhythmogenic ventricular cardiomyopathy (AVC)) was further refined into genetic (inherited or familial) and acquired (non-inherited or secondary) forms. Despite substantial progress in the identification of novel CMP-associated genetic variations, as well as improved clinical recognition diagnoses, the functional consequences of these mutations and the exact details of the signaling pathways leading to hypertrophy, dilation, and/or contractile impairment remain elusive. To date, global research has mainly focused on the genetic factors underlying CMP pathogenesis. However, growing evidence shows that alterations in molecular mediators associated with the diagnosis of CMPs are not always correlated with genetic mutations, suggesting that additional mechanisms, such as epigenetics, may play a role in the onset or progression of CMPs. This review summarizes published findings of inherited CMPs with a specific focus on the potential role of epigenetic mechanisms in regulating these cardiac disorders. |
format | Online Article Text |
id | pubmed-8395924 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83959242021-08-28 The Emerging Role of Epigenetics in Therapeutic Targeting of Cardiomyopathies Pagiatakis, Christina Di Mauro, Vittoria Int J Mol Sci Review Cardiomyopathies (CMPs) are a heterogeneous group of myocardial diseases accountable for the majority of cases of heart failure (HF) and/or sudden cardiac death (SCD) worldwide. With the recent advances in genomics, the original classification of CMPs on the basis of morphological and functional criteria (dilated (DCM), hypertrophic (HCM), restrictive (RCM), and arrhythmogenic ventricular cardiomyopathy (AVC)) was further refined into genetic (inherited or familial) and acquired (non-inherited or secondary) forms. Despite substantial progress in the identification of novel CMP-associated genetic variations, as well as improved clinical recognition diagnoses, the functional consequences of these mutations and the exact details of the signaling pathways leading to hypertrophy, dilation, and/or contractile impairment remain elusive. To date, global research has mainly focused on the genetic factors underlying CMP pathogenesis. However, growing evidence shows that alterations in molecular mediators associated with the diagnosis of CMPs are not always correlated with genetic mutations, suggesting that additional mechanisms, such as epigenetics, may play a role in the onset or progression of CMPs. This review summarizes published findings of inherited CMPs with a specific focus on the potential role of epigenetic mechanisms in regulating these cardiac disorders. MDPI 2021-08-13 /pmc/articles/PMC8395924/ /pubmed/34445422 http://dx.doi.org/10.3390/ijms22168721 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pagiatakis, Christina Di Mauro, Vittoria The Emerging Role of Epigenetics in Therapeutic Targeting of Cardiomyopathies |
title | The Emerging Role of Epigenetics in Therapeutic Targeting of Cardiomyopathies |
title_full | The Emerging Role of Epigenetics in Therapeutic Targeting of Cardiomyopathies |
title_fullStr | The Emerging Role of Epigenetics in Therapeutic Targeting of Cardiomyopathies |
title_full_unstemmed | The Emerging Role of Epigenetics in Therapeutic Targeting of Cardiomyopathies |
title_short | The Emerging Role of Epigenetics in Therapeutic Targeting of Cardiomyopathies |
title_sort | emerging role of epigenetics in therapeutic targeting of cardiomyopathies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395924/ https://www.ncbi.nlm.nih.gov/pubmed/34445422 http://dx.doi.org/10.3390/ijms22168721 |
work_keys_str_mv | AT pagiatakischristina theemergingroleofepigeneticsintherapeutictargetingofcardiomyopathies AT dimaurovittoria theemergingroleofepigeneticsintherapeutictargetingofcardiomyopathies AT pagiatakischristina emergingroleofepigeneticsintherapeutictargetingofcardiomyopathies AT dimaurovittoria emergingroleofepigeneticsintherapeutictargetingofcardiomyopathies |